2010
DOI: 10.1002/adem.200980025
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro Characteristics of Surface‐Modified Biphasic Calcium Phosphate/Poly(L‐Lactide) Biocomposite

Abstract: Surface‐modified biphasic calcium phosphate (BCP)/poly(L‐lactide) (PLLA) biocomposite is shown to have improved microstructure and mechanical properties compared to the unmodified system. In vitro biodegradation and bioactivity of the composite are investigated in simulate body fluid for up to four weeks. Weight changes of the samples and the pH changes of the SBF are recorded. Surface properties of the composite after immersion are characterized by XRD, SEM and EDX analyses. Cyto‐compatibility was determined … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 12 publications
0
10
0
Order By: Relevance
“…Another research group created porous PDLLA/BCP scaffolds and coated them with a hydrophilic PEG/vancomycin composite for both drug delivery purposes and surface modification [ 414 ]. More to the point, both PLGA/BCP [ 415 , 416 ] and PLLA/BCP [ 417 ] biocomposites were fabricated and their cytotoxicity and fibroblast properties were found to be acceptable for natural bone tissue reparation, filling and augmentation [ 418 , 419 ]. Besides, PCL/BCP [ 420 , 421 ], PTMC/BCP [ 422 ] and gelatin/BCP [ 423 , 424 ] biocomposites are known as well.…”
Section: Biocomposites and Hybrid Biomaterials Containing Capo mentioning
confidence: 99%
“…Another research group created porous PDLLA/BCP scaffolds and coated them with a hydrophilic PEG/vancomycin composite for both drug delivery purposes and surface modification [ 414 ]. More to the point, both PLGA/BCP [ 415 , 416 ] and PLLA/BCP [ 417 ] biocomposites were fabricated and their cytotoxicity and fibroblast properties were found to be acceptable for natural bone tissue reparation, filling and augmentation [ 418 , 419 ]. Besides, PCL/BCP [ 420 , 421 ], PTMC/BCP [ 422 ] and gelatin/BCP [ 423 , 424 ] biocomposites are known as well.…”
Section: Biocomposites and Hybrid Biomaterials Containing Capo mentioning
confidence: 99%
“…490 Another research group created porous PDLLA/BCP scaffolds and coated them with a hydrophilic PEG/vancomycin composite for both drug delivery purposes and surface modification. 491 More relevantly, both PLGA/BCP 492,493 and PLLA/ BCP 494 biocomposites were fabricated, and their cytotoxicity and fibroblast properties were found to be acceptable for natural bone tissue reparation, filling and augmentation. 495,496 PCL/BCP 497 and gelatin/BCP 498,499 biocomposites are known as well.…”
Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning
confidence: 99%
“…Previous literature has demonstrated an effective approach to increase the powder solid loading in photocurable slurry through surface modification of CaP powders to convert their wettability from hydrophilic to hydrophobic [ 17–19 ]. Surfactants have been widely used to change the affinity between organic and inorganic phases, as they can reduce aqueous solution surface tension or liquid–liquid interfacial tension [ 20 ]. According to the findings of our previous research, MAEP was selected to modify CaP powders in this study.…”
Section: Discussionmentioning
confidence: 99%